Resource Summary Report

Generated by NIF on Sep 12, 2026

Brilliant Violet 510™ anti-human Fc?RI?

RRID:AB_2564291
Type: Antibody

Proper Citation

BioLegend Cat# 334626, RRID:AB_2564291

Antibody Information

URL: http://antibodyregistry.org/AB_2564291

Proper Citation: BioLegend Cat# 334626, RRID:AB_2564291

Target Antigen: FcepsilonRIalpha

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: FC

Antibody Name: Brilliant Violet 510™ anti-human Fc?RI?

Description: This monoclonal targets FcepsilonRIalpha

Target Organism: human

Clone ID: Clone AER-37 (CRA-1)

Antibody ID: AB_2564291

Vendor: BioLegend

Catalog Number: 334626

Record Creation Time: 20231110T035209+0000

Record Last Update: 20260829T132938+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 510™ anti-human Fc ?RI?.

No alerts have been found for Brilliant Violet 510™ anti-human Fc?RI?.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 6 mentions in open access literature.

Listed below are recent publications. The full list is available at NIF .

Joulia R, et al. (2024) Mast cell activation disrupts interactions between endothelial cells and pericytes during early life allergic asthma. The Journal of clinical investigation, 134(6).

Raeber ME, et al. (2024) Interleukin-2 immunotherapy reveals human regulatory T cell subsets with distinct functional and tissue-homing characteristics. Immunity, 57(9), 2232.

Reid KT, et al. (2024) Cell therapy with human IL-10-producing ILC2s limits xenogeneic graft-versus-host disease by inhibiting pathogenic T cell responses. Cell reports, 44(1), 115102.

Li H, et al. (2023) Abundant binary promoter switches in lineage-determining transcription factors indicate a digital component of cell fate determination. Cell reports, 42(11), 113454.

Wang F, et al. (2021) A basophil-neuronal axis promotes itch. Cell, 184(2), 422.

Chen L, et al. (2018) CD56 Expression Marks Human Group 2 Innate Lymphoid Cell Divergence from a Shared NK Cell and Group 3 Innate Lymphoid Cell Developmental Pathway. Immunity, 49(3), 464.